Abd El-Aziz TM, Stockand JD. Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status. Infect Genet Evol. 2020; 83

Alharbi NK, Padron-Regalado E, Thompson CP. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine. 2017; 35:(30)3780-3788

Altmann DM, Boyton RJ. SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection. Sci Immunol. 2020; 5:(49)

Belen-Apak FB, Sarialioglu F. The old but new: can unfractioned heparin and low molecular weight heparins inhibit proteolytic activation and cellular internalization of SARS-CoV2 by inhibition of host cell proteases?. Med Hypotheses. 2020; 142

Bingham K. The UK Government's Vaccine Taskforce: strategy for protecting the UK and the world. Lancet. 2020;

Chinese Clinical Trial Registry. Trial search. 2020. (accessed 27 October 2020)

Clem AS. Fundamentals of vaccine immunology. J Glob Infect Dis. 2011; 3:(1)73-78

Clinical Trials Register. Investigating a vaccine against COVID-19 US National Library of Medicine. 2020. (accessed 25 November 2020)

European Centre for Disease Prevention and Control. Immune responses and immunity to SARS-CoV-2. 2020. (accessed 2 November 2020)

Folegatti PM, Ewer KJ, Aley PK Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396:(10249)467-478

GAVI. Gavi statement on AstraZeneca/Oxford interim efficacy data. 2020. (accessed 25 November 2020)

Hanney SR, Castle-Clarke S, Grant J How long does biomedical research take? Studying the time taken between biomedical and health research and its translation into products, policy, and practice. Health Res Policy Syst. 2015; 13

Hanney SR, Wooding S, Sussex J From COVID-19 research to vaccine application: why might it take 17 months not 17 years and what are the wider lessons?. Health Res Policy Syst. 2020; 18

Why the Oxford AstraZeneca vaccine is now a global game changer. 2020. (accessed 25 November 2020)

Hodgson SH, Mansatta K, Mallett G What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2020;

ISRCTN Registry. A phase III study to investigate a vaccine against COVID-19. 2020. (accessed 17 November 2020)

London School of Hygiene and Tropical Medicine. A WHO perspective on vaccines and immunization challenges, opportunities and the way forward. 2020. (accessed 17 November 2020)

The global economic impact of COVID-19: a summary of research. 2020. (accessed 17 November 2020)

Mubarak A, Alturaiki W, Hemida MG. Middle East Respiratory Syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J Immunol Res. 2019;

Pfizer. PF-07302048 (BNT162 RNA-based COVID-19 vaccines) protocol C4591001. 2020. (accessed 25 November 2020)

Salazar E, Kuchipudi SV, Christensen PA. Relationship between anti-spike protein antibody titers and SARS-CoV-2 in vitro virus neutralization in convalescent plasma. bioRvix. 2020;

Sanofi. Sanofi and GSK agree with the UK government to supply up to 60 million doses of COVID-19 vaccine. (accessed 29 October 2020)

Tsang TK, Wu P, Lin Y, Lau EH. Effect of changing case definitions for COVID-19 on the epidemic curve and transmission parameters in mainland China: a modelling study. Lancet. 2020; 5:(5)E289-E296

University of Oxford. New study reveals Oxford coronavirus vaccine produces strong immune response. 2020. (accessed 29 October 2020)

Wagner A, Weinberger B. Vaccines to prevent infectious diseases in the older population: immunological challenges and future perspectives. Front Immunol. 2020; 11

Wang Y, Zhang D, Du G Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395:(10236)1569-1578

World Health Organization. Draft landscape of COVID-19 candidate vaccines. 2020. (accessed 2 November 2020)

Wrapp D, Wang N, Corbett KS Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367:(6483)1260-1263

Yu J, Tostanoski LH, Peter L DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020; 369:(6505)806-811

Zhu FC, Li YH, Guan XH Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395:(10240)1845-1854

A COVID-19 vaccine—dare to dream

02 December 2020
Volume 25 · Issue 12


The global desire to produce and deploy a safe and effective vaccine to protect against SARS-CoV-2 infection and the morbidity and mortality subsequent to COVID-19 is unprecedented. The unparalleled speed of research development and access to funding is perhaps equally unique in the history of therapeutic achievement. This article, the third in a series of dedicated to exploring the origins and developments of SARS-CoV-2 within the context of the strategies of infection prevention and control, investigates the theatre behind the extraordinary efforts underpinning the research for therapeutic interventions to halt the COVID-19 pandemic. The Chair of the UK Vaccine Taskforce has stated that the exit strategy depends on a vaccine that is effective in reducing mortality, improving population health by reducing serious disease and protecting the NHS and social care system. This article introduces the major COVID-19 vaccine contenders and considers the challenges and opportunities of an effective global vaccination strategy.

On 12 March 2020, the World Health Organization's (WHO) Director-General Tedros Adhanom Ghebreyesus declared a global pandemic of COVID-19, a disease caused by a novel coronavirus first identified in December 2019; patients in WuHan Province, China were presenting with atypical pneumonia and respiratory distress. The impetus of making such a statement reflected the emerging graphic of the international spread of the disease. Region by region, city by city, health departments around the world were reporting an escalating number of people presenting with acute respiratory infections and experiencing mounting pressure as they struggled to respond to the demands of this new public health threat.

The strategic effect of announcing a pandemic was designed to achieve more than stimulate individual countries to accelerate their efforts; the aim was to strike the right balance between protecting health, preventing economic and social disruption and respecting human rights (WHO, 2020). Learning from previous epidemics and sharing of resources, experience and developments in therapeutic possibilities to slow the virus became a critical element in the global crisis.

Register now to continue reading

Thank you for visiting Community Nursing and reading some of our peer-reviewed resources for district and community nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month